Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas

Go back to Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
(NASDAQ: ARVN) Delayed: 8.31 --0 (-0%)
Previous Close $8.31    52 Week High
Open $8.31    52 Week Low
Day High $8.31    P/E N/A 
Day Low $8.31    EPS
Volume      

Pfizer Inc. (NYSE: PFE) Delayed: 27.64 --0 (-0%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.64    P/E 16.75 
Day Low $27.64    EPS $1.65 
Volume 69,496